In an unusual move, the U.S. Food and Drug Administration has openly suggested that a brand-name drug maker attempted to delay competition after it petitioned the agency to reject generic versions of its biggest-selling medicine. As a result, the FDA plans to ask the U.S. Federal Trade Commission to investigate the company for “anticompetitive business practices.”
The FDA referral was mentioned in a Dec. 15 response to a citizen’s petition filed last month by Endo International (ENDP), which sells Vasostrict, an intravenous medicine used to increase blood pressure in people who experience a sudden decreased blood flow to the brain, heart and kidneys. In the first nine months of this year, Vasostrict sales were $676.7 million, or 30% of companywide revenue.
Create a display name to comment
This name will appear with your comment